Traumatic brain injury: Choosing drugs to assist recovery

Article Type
Changed
Tue, 12/11/2018 - 15:09
Display Headline
Traumatic brain injury: Choosing drugs to assist recovery

Choosing medications for patients with traumatic brain injury (TBI) requires caution; some drugs slow their recovery, and no standard post-TBI treatment exists.

As consulting psychiatrist on a TBI rehabilitation team, I am asked to manage enduring cognitive and emotional problems—aggression, apathy, learning disabilities, dementia—in patients with moderate to severe head injuries. This article describes how we apply available evidence to treat neurobehavioral symptoms in these patients.

Case: An iraq war casualty

The physical medicine and rehabilitation service asks for help in managing agitation, anxiety, and nightmares in Mr. N, age 20, a U.S. combat soldier. While on patrol 2 months ago in Iraq, he suffered a penetrating right frontoparietal brain injury from an improvised explosive device.

Mr. N has undergone a right temporoparietal craniectomy with debridement, ventriculostomy placement, and scalp flap closure. He has had seizures and then pancreatitis—thought to be caused by divalproex prescribed to treat the seizures. Divalproex was replaced with phenytoin at our hospital, and the pancreatitis resolved.

How serious an injury?

TBI ranges from self-limited concussion to devastating, permanent CNS impairment and life-long disability. Brain injuries from sudden impact—from assaults, falls, motor vehicle accidents, combat, or sports—can cause diffuse axonal injury and confusion or unconsciousness, even without radiographic evidence of cerebral bleeding, edema, or mass effect.

No hierarchy or nomenclature is universally accepted for TBI. The term “concussion” is generally used for milder injury and TBI for more-severe injuries.

Concussion. The American Academy of Neurology defines concussion as a trauma-induced alteration in mental status that may or may not involve loss of consciousness. Confusion and amnesia—the hallmarks of concussion—may occur immediately after the head trauma or several minutes later.1 This definition recognizes three concussion grades:

  • Grade 1: confusion lasts
  • Grade 2: confusion persists >15 minutes but without LOC
  • Grade 3: concussion with LOC. The confusional state is marked by disorientation, delayed verbal and motor responses, inattention, incoordination, emotional lability, and slurred or incoherent speech.
TBI. The severity of an injury with LOC is usually determined by four factors: the patient’s initial Glasgow Coma Scale (GCS) score in the emergency department (Table 1),2 neuroimaging, duration of coma, and duration of posttraumatic amnesia (PTA).

  • Mild TBI: GCS 13 to 15, LOC 1,3
  • Moderate TBI: GCS 9 to 12, LOC 30 minutes to 7 days, and PTA 24 hours to 7 days.
  • Severe TBI: GCS ≤8, LOC, and PTA >7 days,4 or any focal neuroimaging abnormalities.3
Table 1

Using Glasgow Coma Scale scores to evaluate brain injury severity

ComponentResponseScore
Best eye responseNo eye opening1
Eye opening to pain2
Eye opening to verbal command3
Eyes open spontaneously4
Best verbal responseNo verbal response1
Incomprehensible sounds2
Inappropriate words3
Confused4
Oriented5
Best motor responseNo motor response1
Extension to pain2
Flexion to pain3
Withdrawal from pain4
Localizing pain5
Obeys commands6
GCS total score ≥12 is mild injury, 9 to 11 is moderate, and ≤8 is severe (90% of patients with scores ≤8 are in a coma). Coma is defined as not opening eyes, not obeying commands, and not saying understandable words. Composite scores with eye, verbal, and motor responses (such as E3V3M5) are clinically more useful than totals.
Source: Reference 2.

Case continued: ‘They’re hurting me’

Mr. N meets criteria for severe TBI. He is periodically agitated and aggressive and refuses to return to physical therapy, complaining that rehabilitation nurses are intentionally hurting him. He occasionally hits the staff and throws things. His medications include:

  • phenytoin, 100 mg every 6 hours for seizure prophylaxis
  • lamotrigine, 50 mg bid for seizure prophylaxis
  • zolpidem, 5 mg as needed at bedtime for pain
  • methadone, 10 mg/d for pain
  • oxycodone, 5 mg every 4 hours as needed for breakthrough pain.
Mr. N’s recovery 2 months after injury is rated as Rancho level IV, indicating that he remains confused and agitated. He requires maximal assistance with bed mobility and transfers, upper and lower extremity dressing, and rolling his wheelchair with both feet. He is incontinent of bowel and bladder.

Assessing progress

For patients such as Mr. N, TBI recovery progress is measured with the Rancho Los Amigos Scale.

The original Rancho scale—developed in 1972 by staff at the Rancho Los Amigos rehabilitation hospital in Downey, CA—described eight levels of cognitive and adaptive functioning, from coma and total care through normal cognition and independence. A 1997 revised version separates the highest cognitive functioning level (VIII, purposeful, appropriate function) into three parts, expanding the scale to 10 levels (Table 2).5

Of course, not all TBI patients begin recovery at Rancho level I, and unfortunately not all achieve level X. Some experience dementia caused by head trauma, with persistent memory impairment and cognitive deficits in language, apraxia, agnosia, or executive function.6

 

 

Most patients recover as predicted by the initial injury’s severity. Others experience diffuse cerebral swelling with sudden, rapid deterioration after what appeared to be a grade 1 or grade 2 concussion. Diffuse cerebral swelling is sometimes considered a “second-impact syndrome,” but it can also occur after a single impact.7 A second TBI is not universally believed to cause the precipitous decline, but animal studies suggest an additive effect of rapid sequential TBI.8

Table 2

10-level Rancho Los Amigos Scale for assessing TBI recovery

LevelCognitive and adaptive functionAssistance required
INo responseTotal assistance
IIGeneralized responseTotal assistance
IIILocalized responseTotal assistance
IVConfused/agitatedMaximal assistance
VConfused, inappropriate non-agitatedMaximal assistance
VIConfused, appropriateModerate assistance
VIIAutomatic, appropriateMinimal assistance
VIIIPurposeful, appropriateStand-by assistance
IXPurposeful, appropriateStand-by assistanceon request
XPurposeful, appropriateModified independent
Source: Traumatic Brain Injury Resource Guide. www.neuroskills.com.
Post-TBI syndromes. Concussion and TBI share diffuse axonal injury as a putative pathophysiologic mechanism. Post-concussion and post-TBI syndromes are similar but vary in severity and duration. Signs and symptoms include headache, light-headedness or dizziness, poor attention and concentration, irritability with low frustration tolerance, anxiety or depression, sensitivity to bright light or loud noise, and sleep disturbance.1

Recovery for a patient such as Mr. N with Rancho level IV to V TBI may be complicated by marked mood lability, spontaneous aggression, psychomotor agitation, extremely short attention with marked distractibility, little to no short-term memory, and noncooperation with treatment and care. Patients may also show disorders of diminished motivation, characterized by normal consciousness but decreased goal-directed behavior and affective flattening.9

Case continued: Calling in reinforcements

Besides combat nightmares, Mr. N is experiencing other signs of posttraumatic stress disorder (PTSD): intrusive memories of dead comrades, anhedonia, insomnia, irritability, and hypervigilance. We recommend a trial of citalopram, 10 mg/d, but within 1 week he becomes more irritable, agitated, and aggressive, with worsening sleep. We arrange a meeting to obtain collateral information from Mr. N’s aunt, mother, and clinical psychologist. We learn that a first-degree relative had bipolar disorder, and Mr. N lived with various relatives during childhood.

As a child, Mr. N was easily angered, hyperactive, unpredictably aggressive with peers, and impulsive. He was diagnosed with “explosive disorder” at age 8. A psychiatrist prescribed methylphenidate (which helped) and paroxetine (which worsened his behavior and aggression). Based on this history, we make a presumptive diagnosis of comorbid bipolar disorder.

Treating psychopathology

Comorbidities. Adolescents and adults with pre-existing attention-deficit/hyperactivity disorder or bipolar disorder may be predisposed to carelessness or risk taking that lead to accidents and TBI. Likewise, alcoholism and substance use disorders are risk factors for head injuries. These pre-existing conditions will complicate the post-TBI course and must be treated concurrently.

Depression and PTSD may follow a head injury and complicate recovery. In fact, post-TBI symptoms—poor sleep, poor memory and concentration, and irritability—are common to both depression and PTSD.

A team approach. Regardless of its severity or recovery stage, TBI requires multidisciplinary treatment. Physical, occupational, and speech therapies are essential initially. As recovery progresses, vocational rehabilitation may need to be added. Throughout rehabilitation, supportive individual and family therapy can help patients reintegrate into the community. Psychologists, neuropsychologists, and clinical social workers are indispensable to the treatment team.

Medication precautions

Using medications to manage post-TBI syndromes is difficult and controversial. No standard regimen exists, and few clinical trials guide treatment. Small, uncontrolled studies (human and animal) suggest commonly prescribed drugs may worsen outcomes (Table 3).10,11 For example:

  • Cognitive function improved in three TBI patients after thioridazine was discontinued in two and haloperidol in one.12
  • Haloperidol given to 11 patients with TBI made no difference in rehabilitation outcomes when compared with 15 patients who did not receive the antipsychotic. Those receiving haloperidol also had longer post-trauma amnesia (5 to 30 weeks), compared with the untreated group (1 to 18 weeks).13
  • In animal studies of TBI, motor recovery was slowed with haloperidol but not olanzapine,14,15 and with clonidine,16 phenytoin,17 and trazodone.18 Phenobarbitol.19 and diazepam20 have been associated with delayed behavioral recovery and chronic behavior problems, respectively, in rats with TBI. How these agents might affect human patients is speculative.
Table 3

Medications with potential to impede TBI recovery*

ClassMedications
Alpha-2 agonistClonidine
AntidepressantTrazodone
AntiepilepticPhenytoin, phenobarbital
BenzodiazepineDiazepam
NeurolepticHaloperidol, thioridazine
*Suggested by animal or clinical studies
Source: References 11-20
Apathy and inattention. A review of 63 papers found no strong evidence that drugs are effective for TBI’s neurobehavioral disorders, although weak evidence shows that some drug classes can reduce target symptoms—such as psychostimulants for apathy, inattention, and slowness (Table 4).21 Other reports suggest reasonable approaches:

  • Psychostimulants have improved recovery of motor function in animal trials if given before physical therapy.14
  • Stimulants and dopaminergic agonists such as bromocriptine and amantadine might help disorders of diminished motivation.22
  • Dextroamphetamine and methylphenidate have improved impulsivity, memory, and concentration in a patient with TBI.23
 

 

Table 4

Drugs considered safe and effective
for TBI neurobehavioral symptoms

Target symptom(s)DrugUsual daily dosage*
ApathyAmantadine100 to 400 mg
Bromocriptine1.25 to 100 mg
CognitionDonepezil 
InattentionDextroamphetamine5 to 60 mg
Methylphenidate10 to 60 mg
Depression, PTSD symptomsFluoxetine20 to 80 mg
Agitation, mood stabilizationAnticonvulsants 
Lamotrigine25 to 200 mg
Divalproex sodium10 to 15 mg/kg/day
Carbamazepine400 to 1,600 mg
Atypical antipsychotics 
Olanzapine2.5 to 20 mg
Quetiapine50 to 800 mg
Risperidone0.5 to 6 mg
Ziprasidone20 to 160 mg
Beta blocker 
Propranolol20 to 480 mg
PTSD: posttraumatic stress disorder
* Dosage may be divided; see full prescribing information.
† Adjust dosage to achieve serum level of 50 to 100 mcg/mL.
‡ Adjust dosage to achieve serum level of 4 to 12 mcg/mL.
Agitation and aggression in TBI are more difficult to treat than apathy or inattention. Some authors15,24 suggest that atypical antipsychotics are more effective than neuroleptics for these symptoms and less likely to cause adverse effects (Table 5).

Small studies of anticonvulsants for post-TBI agitation report:

  • valproic acid might improve behavioral control and decrease aggression, and it did not worsen performance on neuropsychological testing
  • carbamazepine reduced agitation in seven TBI patients and reduced anger outbursts in 8 of 10 others
  • gabapentin caused paradoxical effects in two TBI patients25
  • lamotrigine improved agitation in one TBI patient.26
Five studies show preliminary evidence that beta blockers (usually propranolol) can reduce assaultive behavior and temper outbursts in TBI patients. Relatively high dosages are usually needed, such as:

  • propranolol, 420 to 520 mg/d
  • pindolol, 60 mg/d
  • metoprolol, 200 mg/d.21
Table 5

Dosing atypical antipsychotics
for agitation and aggression in TBI

DrugInitial daily dosage*Maximum daily dosage*
Aripiprazole2.5 to 5 mg30 mg
Olanzapine2.5 mg20 mg
Quetiapine12.5 to 50 mg800 mg
Risperidone0.25 mg8 mg
Ziprasidone20 mg160 mg
*Daily dosages may be divided
Psychiatric comorbidity. In TBI patients with comorbid bipolar disorder, mood stabilization with an atypical antipsychotic, anticonvulsant (divalproex sodium, carbamazepine), or a combination of the two is first-line therapy. No evidence suggests that using lithium in the absence of mania improves aggression, agitation, or other neurobehavioral symptoms in TBI patients.21

Depression and PTSD in TBI patients are considered indications for selective serotonin reuptake inhibitors (SSRIs). Animal data suggest that fluoxetine is safe for patients with TBI,27 though no human data have been published.

For PTSD with bipolar depression, we usually prescribe lamotrigine or combine an atypical antipsychotic with an SSRI. Lithium would be second-line therapy. PTSD with bipolar mania is more difficult to treat because little evidence guides medication choices. As with depression and PTSD, we usually combine an atypical antipsychotic with an SSRI. We try to control manic and psychotic symptoms first, then add the SSRI for anxiety after the mood becomes more stable.

Cognitive impairment. A dozen published studies and case reports indicate that donepezil improves cognition in subacute and chronic TBI. For example:

  • An open-label trial showed subjective improvement in cognitive functions in 8 of 10 patients given donepezil.28
  • In a double-blind, placebo-controlled, crossover trial, short-term memory and attention improved with donepezil in 18 patients with post-acute TBI, as shown by neuropsychological test scores.29
  • A retrospective case-control study showed no significant difference in cognitive outcome between controls and 18 patients prescribed donepezil but did suggest that cognition improved more rapidly when patients started donepezil earlier in recovery.30

Case continued: Back to rehab

We replace Mr. N’s phenytoin with carbamazepine, 700 mg/d (serum level about 12 mcg/mL), discontinue citalopram, and start him on quetiapine as a mood stabilizer, titrating the dosage to 600 mg/d over 3 weeks. We select quetiapine based on experience using it as a mood stabilizer and carbamazepine for additional mood stabilization and seizure prophylaxis.

We continue methadone and oxycodone at the same dosages for pain management, with good results. We eventually switch him from zolpidem to trazodone, 50 mg as needed at bedtime. We discontinue lamotrigine because he is no longer having seizures.

Mr. N tolerates quetiapine and carbamazepine well. The nursing staff reports he is much less irritable and aggressive and his sleep has improved, but he is not oversedated. He returns to and participates in physical, occupational, and speech therapies.

Tips for using medications

Many TBI patients are unusually sensitive to or intolerant of medication side effects. Because no randomized, controlled clinical trials support using any medication in these patients, be cautious. The following recommendations can help:

  • Use psychotropics with a low risk of complications.
  • Start with low dosages and increase gradually to assess side effects and efficacy of medication trials.
  • Give full trials and adequate dosing before you decide a medication has not improved symptoms sufficiently.
  • Monitor closely for side effects.
  • Seek information from family members to evaluate a medication’s effectiveness, as patients’ cognitive deficits may limit their ability to reliably report symptoms.
 

 

Related resources

  • Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press, 2005.
  • Traumatic Brain Injury Resource Guide. www.neuroskills.com
Drug brand names

  • Amantadine • Symmetrel
  • Bromocriptine • Parlodel
  • Carbamazepine • Tegretol
  • Citalopram • Celexa
  • Clonidine • Catapres
  • Dextroamphetamine • Dexedrine
  • Diazepam • Valium
  • Divalproex sodium • Depakote
  • Donepezil • Aricept
  • Fluoxetine • Prozac
  • Gabapentin • Neurontin
  • Haloperidol • Haldol
  • Lamotrigine • Lamictal
  • Methadone • Dolophine
  • Methylphenidate • Ritalin
  • Metoprolol • Lopressor
  • Olanzapine • Zyprexa
  • Oxycodone • Oxycontin
  • Paroxetine • Paxil
  • Phenobarbital • Luminal
  • Phenytoin • Dilantin
  • Pindolol • Visken
  • Propranolol • Inderal
  • Quetiapine • Seroquel
  • Risperidone • Risperdal
  • Thioridazine • Mellaril
  • Trazodone • Desyrel
  • Ziprasidone • Geodon
  • Zolpidem • Ambien
Disclosures

The author reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References

1. American Academy of Neurology. Practice parameter: The management of concussion in sports. Neurology 1997;48:581-5.

2. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974;2(7872):81-4.

3. Alexander MP. Mild traumatic brain injury: Pathophysiology, natural history, and clinical management. Neurology 1995;45:1253-60.

4. Arlinghaus KA, Shoaib AM, Price TRP. Neuropsychiatric assessment. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press; 2005:59-78.

5. Hagen C, Malkmus D, Durham P. Communication Disorders Service, Rancho Los Amigos Rehabilitation Hospital, Downey, CA, 1972 (rev. 1997).

6. Diagnostic and statistical manual of mental disorders (4th ed, text rev). Washington, DC: American Psychiatric Association; 2000.

7. McCrory P. Does second impact syndrome exist? Clin J Sport Med 2001;11:144-9.

8. Vagnozzi R, Signoretti S, Tavazzi B, et al. Hypothesis of the postconcussive vulnerable brain: experimental evidence of its metabolic occurrence. Neurosurgery 2005;57:164-71.

9. Marin RS, Chakravorty S. Disorders of diminished motivation. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA; American Psychiatric Press; 2005:337-52.

10. Goldstein LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry 1995;58:753-5.

11. Phillips JP, Devier DJ, Feeney DM. Rehabilitation pharmacology bridging laboratory work to clinical application. J Head Trauma Rehabil 2003;18:342-56.

12. Stanislaw SL. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Injury 1997;11:335-41.

13. Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil 1985;66:30-4.

14. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-7.

15. Wilson MS, Gibson CL, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003;82:871-9.

16. Goldstein LB, Davis JN. Clonidine impairs recovery of beamwalking after a sensorimotor cortex lesion in the rat. Brain Research 1990;508:305-9.

17. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Research 1986;376:71-7.

18. Boyeson MG, Harmon RL. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil 1993;72:286-93.

19. Hernandez TD, Holling LC. Disruption of behavioral recovery by the anticonvulsant phenobarbital. Brain Research 1994;635:300-6.

20. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Research 1986;379:104-11.

21. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behavior disorders in traumatic brain injury patients. Brain Injury 2004;18:1-31.

22. Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatric Annals 1997;27(1):44-9.

23. Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987;175:106-10.

24. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil 2003;18:177-95.

25. Lombard LA, Zafonte RD. Agitation after traumatic brain injury: considerations and treatment options. Am J Phys Med Rehabil 2005;84:797-812.

26. Pachet A, Friesen S, Winkelaar D, Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Injury 2003;17:715-22.

27. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline, and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil 1994;73:76-83.

28. Khateb A, Ammann J, Annoni JM, Diserens K. Cognition enhancing effects of onepezil in traumatic brain injury (abstract). Eur Neurol 2005;54:39-45.

29. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004;85:1005-55.

30. Walker W, Seel R, Gibellato M, et al. The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj 2004;18:739-50.

Article PDF
Author and Disclosure Information

John P. Daniels, MD
Assistant professor of psychiatry, University of Minnesota,
Staff psychiatrist, Department of Veterans Affairs Medical Center,
Minneapolis, MN

Issue
Current Psychiatry - 05(05)
Publications
Page Number
57-68
Sections
Author and Disclosure Information

John P. Daniels, MD
Assistant professor of psychiatry, University of Minnesota,
Staff psychiatrist, Department of Veterans Affairs Medical Center,
Minneapolis, MN

Author and Disclosure Information

John P. Daniels, MD
Assistant professor of psychiatry, University of Minnesota,
Staff psychiatrist, Department of Veterans Affairs Medical Center,
Minneapolis, MN

Article PDF
Article PDF

Choosing medications for patients with traumatic brain injury (TBI) requires caution; some drugs slow their recovery, and no standard post-TBI treatment exists.

As consulting psychiatrist on a TBI rehabilitation team, I am asked to manage enduring cognitive and emotional problems—aggression, apathy, learning disabilities, dementia—in patients with moderate to severe head injuries. This article describes how we apply available evidence to treat neurobehavioral symptoms in these patients.

Case: An iraq war casualty

The physical medicine and rehabilitation service asks for help in managing agitation, anxiety, and nightmares in Mr. N, age 20, a U.S. combat soldier. While on patrol 2 months ago in Iraq, he suffered a penetrating right frontoparietal brain injury from an improvised explosive device.

Mr. N has undergone a right temporoparietal craniectomy with debridement, ventriculostomy placement, and scalp flap closure. He has had seizures and then pancreatitis—thought to be caused by divalproex prescribed to treat the seizures. Divalproex was replaced with phenytoin at our hospital, and the pancreatitis resolved.

How serious an injury?

TBI ranges from self-limited concussion to devastating, permanent CNS impairment and life-long disability. Brain injuries from sudden impact—from assaults, falls, motor vehicle accidents, combat, or sports—can cause diffuse axonal injury and confusion or unconsciousness, even without radiographic evidence of cerebral bleeding, edema, or mass effect.

No hierarchy or nomenclature is universally accepted for TBI. The term “concussion” is generally used for milder injury and TBI for more-severe injuries.

Concussion. The American Academy of Neurology defines concussion as a trauma-induced alteration in mental status that may or may not involve loss of consciousness. Confusion and amnesia—the hallmarks of concussion—may occur immediately after the head trauma or several minutes later.1 This definition recognizes three concussion grades:

  • Grade 1: confusion lasts
  • Grade 2: confusion persists >15 minutes but without LOC
  • Grade 3: concussion with LOC. The confusional state is marked by disorientation, delayed verbal and motor responses, inattention, incoordination, emotional lability, and slurred or incoherent speech.
TBI. The severity of an injury with LOC is usually determined by four factors: the patient’s initial Glasgow Coma Scale (GCS) score in the emergency department (Table 1),2 neuroimaging, duration of coma, and duration of posttraumatic amnesia (PTA).

  • Mild TBI: GCS 13 to 15, LOC 1,3
  • Moderate TBI: GCS 9 to 12, LOC 30 minutes to 7 days, and PTA 24 hours to 7 days.
  • Severe TBI: GCS ≤8, LOC, and PTA >7 days,4 or any focal neuroimaging abnormalities.3
Table 1

Using Glasgow Coma Scale scores to evaluate brain injury severity

ComponentResponseScore
Best eye responseNo eye opening1
Eye opening to pain2
Eye opening to verbal command3
Eyes open spontaneously4
Best verbal responseNo verbal response1
Incomprehensible sounds2
Inappropriate words3
Confused4
Oriented5
Best motor responseNo motor response1
Extension to pain2
Flexion to pain3
Withdrawal from pain4
Localizing pain5
Obeys commands6
GCS total score ≥12 is mild injury, 9 to 11 is moderate, and ≤8 is severe (90% of patients with scores ≤8 are in a coma). Coma is defined as not opening eyes, not obeying commands, and not saying understandable words. Composite scores with eye, verbal, and motor responses (such as E3V3M5) are clinically more useful than totals.
Source: Reference 2.

Case continued: ‘They’re hurting me’

Mr. N meets criteria for severe TBI. He is periodically agitated and aggressive and refuses to return to physical therapy, complaining that rehabilitation nurses are intentionally hurting him. He occasionally hits the staff and throws things. His medications include:

  • phenytoin, 100 mg every 6 hours for seizure prophylaxis
  • lamotrigine, 50 mg bid for seizure prophylaxis
  • zolpidem, 5 mg as needed at bedtime for pain
  • methadone, 10 mg/d for pain
  • oxycodone, 5 mg every 4 hours as needed for breakthrough pain.
Mr. N’s recovery 2 months after injury is rated as Rancho level IV, indicating that he remains confused and agitated. He requires maximal assistance with bed mobility and transfers, upper and lower extremity dressing, and rolling his wheelchair with both feet. He is incontinent of bowel and bladder.

Assessing progress

For patients such as Mr. N, TBI recovery progress is measured with the Rancho Los Amigos Scale.

The original Rancho scale—developed in 1972 by staff at the Rancho Los Amigos rehabilitation hospital in Downey, CA—described eight levels of cognitive and adaptive functioning, from coma and total care through normal cognition and independence. A 1997 revised version separates the highest cognitive functioning level (VIII, purposeful, appropriate function) into three parts, expanding the scale to 10 levels (Table 2).5

Of course, not all TBI patients begin recovery at Rancho level I, and unfortunately not all achieve level X. Some experience dementia caused by head trauma, with persistent memory impairment and cognitive deficits in language, apraxia, agnosia, or executive function.6

 

 

Most patients recover as predicted by the initial injury’s severity. Others experience diffuse cerebral swelling with sudden, rapid deterioration after what appeared to be a grade 1 or grade 2 concussion. Diffuse cerebral swelling is sometimes considered a “second-impact syndrome,” but it can also occur after a single impact.7 A second TBI is not universally believed to cause the precipitous decline, but animal studies suggest an additive effect of rapid sequential TBI.8

Table 2

10-level Rancho Los Amigos Scale for assessing TBI recovery

LevelCognitive and adaptive functionAssistance required
INo responseTotal assistance
IIGeneralized responseTotal assistance
IIILocalized responseTotal assistance
IVConfused/agitatedMaximal assistance
VConfused, inappropriate non-agitatedMaximal assistance
VIConfused, appropriateModerate assistance
VIIAutomatic, appropriateMinimal assistance
VIIIPurposeful, appropriateStand-by assistance
IXPurposeful, appropriateStand-by assistanceon request
XPurposeful, appropriateModified independent
Source: Traumatic Brain Injury Resource Guide. www.neuroskills.com.
Post-TBI syndromes. Concussion and TBI share diffuse axonal injury as a putative pathophysiologic mechanism. Post-concussion and post-TBI syndromes are similar but vary in severity and duration. Signs and symptoms include headache, light-headedness or dizziness, poor attention and concentration, irritability with low frustration tolerance, anxiety or depression, sensitivity to bright light or loud noise, and sleep disturbance.1

Recovery for a patient such as Mr. N with Rancho level IV to V TBI may be complicated by marked mood lability, spontaneous aggression, psychomotor agitation, extremely short attention with marked distractibility, little to no short-term memory, and noncooperation with treatment and care. Patients may also show disorders of diminished motivation, characterized by normal consciousness but decreased goal-directed behavior and affective flattening.9

Case continued: Calling in reinforcements

Besides combat nightmares, Mr. N is experiencing other signs of posttraumatic stress disorder (PTSD): intrusive memories of dead comrades, anhedonia, insomnia, irritability, and hypervigilance. We recommend a trial of citalopram, 10 mg/d, but within 1 week he becomes more irritable, agitated, and aggressive, with worsening sleep. We arrange a meeting to obtain collateral information from Mr. N’s aunt, mother, and clinical psychologist. We learn that a first-degree relative had bipolar disorder, and Mr. N lived with various relatives during childhood.

As a child, Mr. N was easily angered, hyperactive, unpredictably aggressive with peers, and impulsive. He was diagnosed with “explosive disorder” at age 8. A psychiatrist prescribed methylphenidate (which helped) and paroxetine (which worsened his behavior and aggression). Based on this history, we make a presumptive diagnosis of comorbid bipolar disorder.

Treating psychopathology

Comorbidities. Adolescents and adults with pre-existing attention-deficit/hyperactivity disorder or bipolar disorder may be predisposed to carelessness or risk taking that lead to accidents and TBI. Likewise, alcoholism and substance use disorders are risk factors for head injuries. These pre-existing conditions will complicate the post-TBI course and must be treated concurrently.

Depression and PTSD may follow a head injury and complicate recovery. In fact, post-TBI symptoms—poor sleep, poor memory and concentration, and irritability—are common to both depression and PTSD.

A team approach. Regardless of its severity or recovery stage, TBI requires multidisciplinary treatment. Physical, occupational, and speech therapies are essential initially. As recovery progresses, vocational rehabilitation may need to be added. Throughout rehabilitation, supportive individual and family therapy can help patients reintegrate into the community. Psychologists, neuropsychologists, and clinical social workers are indispensable to the treatment team.

Medication precautions

Using medications to manage post-TBI syndromes is difficult and controversial. No standard regimen exists, and few clinical trials guide treatment. Small, uncontrolled studies (human and animal) suggest commonly prescribed drugs may worsen outcomes (Table 3).10,11 For example:

  • Cognitive function improved in three TBI patients after thioridazine was discontinued in two and haloperidol in one.12
  • Haloperidol given to 11 patients with TBI made no difference in rehabilitation outcomes when compared with 15 patients who did not receive the antipsychotic. Those receiving haloperidol also had longer post-trauma amnesia (5 to 30 weeks), compared with the untreated group (1 to 18 weeks).13
  • In animal studies of TBI, motor recovery was slowed with haloperidol but not olanzapine,14,15 and with clonidine,16 phenytoin,17 and trazodone.18 Phenobarbitol.19 and diazepam20 have been associated with delayed behavioral recovery and chronic behavior problems, respectively, in rats with TBI. How these agents might affect human patients is speculative.
Table 3

Medications with potential to impede TBI recovery*

ClassMedications
Alpha-2 agonistClonidine
AntidepressantTrazodone
AntiepilepticPhenytoin, phenobarbital
BenzodiazepineDiazepam
NeurolepticHaloperidol, thioridazine
*Suggested by animal or clinical studies
Source: References 11-20
Apathy and inattention. A review of 63 papers found no strong evidence that drugs are effective for TBI’s neurobehavioral disorders, although weak evidence shows that some drug classes can reduce target symptoms—such as psychostimulants for apathy, inattention, and slowness (Table 4).21 Other reports suggest reasonable approaches:

  • Psychostimulants have improved recovery of motor function in animal trials if given before physical therapy.14
  • Stimulants and dopaminergic agonists such as bromocriptine and amantadine might help disorders of diminished motivation.22
  • Dextroamphetamine and methylphenidate have improved impulsivity, memory, and concentration in a patient with TBI.23
 

 

Table 4

Drugs considered safe and effective
for TBI neurobehavioral symptoms

Target symptom(s)DrugUsual daily dosage*
ApathyAmantadine100 to 400 mg
Bromocriptine1.25 to 100 mg
CognitionDonepezil 
InattentionDextroamphetamine5 to 60 mg
Methylphenidate10 to 60 mg
Depression, PTSD symptomsFluoxetine20 to 80 mg
Agitation, mood stabilizationAnticonvulsants 
Lamotrigine25 to 200 mg
Divalproex sodium10 to 15 mg/kg/day
Carbamazepine400 to 1,600 mg
Atypical antipsychotics 
Olanzapine2.5 to 20 mg
Quetiapine50 to 800 mg
Risperidone0.5 to 6 mg
Ziprasidone20 to 160 mg
Beta blocker 
Propranolol20 to 480 mg
PTSD: posttraumatic stress disorder
* Dosage may be divided; see full prescribing information.
† Adjust dosage to achieve serum level of 50 to 100 mcg/mL.
‡ Adjust dosage to achieve serum level of 4 to 12 mcg/mL.
Agitation and aggression in TBI are more difficult to treat than apathy or inattention. Some authors15,24 suggest that atypical antipsychotics are more effective than neuroleptics for these symptoms and less likely to cause adverse effects (Table 5).

Small studies of anticonvulsants for post-TBI agitation report:

  • valproic acid might improve behavioral control and decrease aggression, and it did not worsen performance on neuropsychological testing
  • carbamazepine reduced agitation in seven TBI patients and reduced anger outbursts in 8 of 10 others
  • gabapentin caused paradoxical effects in two TBI patients25
  • lamotrigine improved agitation in one TBI patient.26
Five studies show preliminary evidence that beta blockers (usually propranolol) can reduce assaultive behavior and temper outbursts in TBI patients. Relatively high dosages are usually needed, such as:

  • propranolol, 420 to 520 mg/d
  • pindolol, 60 mg/d
  • metoprolol, 200 mg/d.21
Table 5

Dosing atypical antipsychotics
for agitation and aggression in TBI

DrugInitial daily dosage*Maximum daily dosage*
Aripiprazole2.5 to 5 mg30 mg
Olanzapine2.5 mg20 mg
Quetiapine12.5 to 50 mg800 mg
Risperidone0.25 mg8 mg
Ziprasidone20 mg160 mg
*Daily dosages may be divided
Psychiatric comorbidity. In TBI patients with comorbid bipolar disorder, mood stabilization with an atypical antipsychotic, anticonvulsant (divalproex sodium, carbamazepine), or a combination of the two is first-line therapy. No evidence suggests that using lithium in the absence of mania improves aggression, agitation, or other neurobehavioral symptoms in TBI patients.21

Depression and PTSD in TBI patients are considered indications for selective serotonin reuptake inhibitors (SSRIs). Animal data suggest that fluoxetine is safe for patients with TBI,27 though no human data have been published.

For PTSD with bipolar depression, we usually prescribe lamotrigine or combine an atypical antipsychotic with an SSRI. Lithium would be second-line therapy. PTSD with bipolar mania is more difficult to treat because little evidence guides medication choices. As with depression and PTSD, we usually combine an atypical antipsychotic with an SSRI. We try to control manic and psychotic symptoms first, then add the SSRI for anxiety after the mood becomes more stable.

Cognitive impairment. A dozen published studies and case reports indicate that donepezil improves cognition in subacute and chronic TBI. For example:

  • An open-label trial showed subjective improvement in cognitive functions in 8 of 10 patients given donepezil.28
  • In a double-blind, placebo-controlled, crossover trial, short-term memory and attention improved with donepezil in 18 patients with post-acute TBI, as shown by neuropsychological test scores.29
  • A retrospective case-control study showed no significant difference in cognitive outcome between controls and 18 patients prescribed donepezil but did suggest that cognition improved more rapidly when patients started donepezil earlier in recovery.30

Case continued: Back to rehab

We replace Mr. N’s phenytoin with carbamazepine, 700 mg/d (serum level about 12 mcg/mL), discontinue citalopram, and start him on quetiapine as a mood stabilizer, titrating the dosage to 600 mg/d over 3 weeks. We select quetiapine based on experience using it as a mood stabilizer and carbamazepine for additional mood stabilization and seizure prophylaxis.

We continue methadone and oxycodone at the same dosages for pain management, with good results. We eventually switch him from zolpidem to trazodone, 50 mg as needed at bedtime. We discontinue lamotrigine because he is no longer having seizures.

Mr. N tolerates quetiapine and carbamazepine well. The nursing staff reports he is much less irritable and aggressive and his sleep has improved, but he is not oversedated. He returns to and participates in physical, occupational, and speech therapies.

Tips for using medications

Many TBI patients are unusually sensitive to or intolerant of medication side effects. Because no randomized, controlled clinical trials support using any medication in these patients, be cautious. The following recommendations can help:

  • Use psychotropics with a low risk of complications.
  • Start with low dosages and increase gradually to assess side effects and efficacy of medication trials.
  • Give full trials and adequate dosing before you decide a medication has not improved symptoms sufficiently.
  • Monitor closely for side effects.
  • Seek information from family members to evaluate a medication’s effectiveness, as patients’ cognitive deficits may limit their ability to reliably report symptoms.
 

 

Related resources

  • Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press, 2005.
  • Traumatic Brain Injury Resource Guide. www.neuroskills.com
Drug brand names

  • Amantadine • Symmetrel
  • Bromocriptine • Parlodel
  • Carbamazepine • Tegretol
  • Citalopram • Celexa
  • Clonidine • Catapres
  • Dextroamphetamine • Dexedrine
  • Diazepam • Valium
  • Divalproex sodium • Depakote
  • Donepezil • Aricept
  • Fluoxetine • Prozac
  • Gabapentin • Neurontin
  • Haloperidol • Haldol
  • Lamotrigine • Lamictal
  • Methadone • Dolophine
  • Methylphenidate • Ritalin
  • Metoprolol • Lopressor
  • Olanzapine • Zyprexa
  • Oxycodone • Oxycontin
  • Paroxetine • Paxil
  • Phenobarbital • Luminal
  • Phenytoin • Dilantin
  • Pindolol • Visken
  • Propranolol • Inderal
  • Quetiapine • Seroquel
  • Risperidone • Risperdal
  • Thioridazine • Mellaril
  • Trazodone • Desyrel
  • Ziprasidone • Geodon
  • Zolpidem • Ambien
Disclosures

The author reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Choosing medications for patients with traumatic brain injury (TBI) requires caution; some drugs slow their recovery, and no standard post-TBI treatment exists.

As consulting psychiatrist on a TBI rehabilitation team, I am asked to manage enduring cognitive and emotional problems—aggression, apathy, learning disabilities, dementia—in patients with moderate to severe head injuries. This article describes how we apply available evidence to treat neurobehavioral symptoms in these patients.

Case: An iraq war casualty

The physical medicine and rehabilitation service asks for help in managing agitation, anxiety, and nightmares in Mr. N, age 20, a U.S. combat soldier. While on patrol 2 months ago in Iraq, he suffered a penetrating right frontoparietal brain injury from an improvised explosive device.

Mr. N has undergone a right temporoparietal craniectomy with debridement, ventriculostomy placement, and scalp flap closure. He has had seizures and then pancreatitis—thought to be caused by divalproex prescribed to treat the seizures. Divalproex was replaced with phenytoin at our hospital, and the pancreatitis resolved.

How serious an injury?

TBI ranges from self-limited concussion to devastating, permanent CNS impairment and life-long disability. Brain injuries from sudden impact—from assaults, falls, motor vehicle accidents, combat, or sports—can cause diffuse axonal injury and confusion or unconsciousness, even without radiographic evidence of cerebral bleeding, edema, or mass effect.

No hierarchy or nomenclature is universally accepted for TBI. The term “concussion” is generally used for milder injury and TBI for more-severe injuries.

Concussion. The American Academy of Neurology defines concussion as a trauma-induced alteration in mental status that may or may not involve loss of consciousness. Confusion and amnesia—the hallmarks of concussion—may occur immediately after the head trauma or several minutes later.1 This definition recognizes three concussion grades:

  • Grade 1: confusion lasts
  • Grade 2: confusion persists >15 minutes but without LOC
  • Grade 3: concussion with LOC. The confusional state is marked by disorientation, delayed verbal and motor responses, inattention, incoordination, emotional lability, and slurred or incoherent speech.
TBI. The severity of an injury with LOC is usually determined by four factors: the patient’s initial Glasgow Coma Scale (GCS) score in the emergency department (Table 1),2 neuroimaging, duration of coma, and duration of posttraumatic amnesia (PTA).

  • Mild TBI: GCS 13 to 15, LOC 1,3
  • Moderate TBI: GCS 9 to 12, LOC 30 minutes to 7 days, and PTA 24 hours to 7 days.
  • Severe TBI: GCS ≤8, LOC, and PTA >7 days,4 or any focal neuroimaging abnormalities.3
Table 1

Using Glasgow Coma Scale scores to evaluate brain injury severity

ComponentResponseScore
Best eye responseNo eye opening1
Eye opening to pain2
Eye opening to verbal command3
Eyes open spontaneously4
Best verbal responseNo verbal response1
Incomprehensible sounds2
Inappropriate words3
Confused4
Oriented5
Best motor responseNo motor response1
Extension to pain2
Flexion to pain3
Withdrawal from pain4
Localizing pain5
Obeys commands6
GCS total score ≥12 is mild injury, 9 to 11 is moderate, and ≤8 is severe (90% of patients with scores ≤8 are in a coma). Coma is defined as not opening eyes, not obeying commands, and not saying understandable words. Composite scores with eye, verbal, and motor responses (such as E3V3M5) are clinically more useful than totals.
Source: Reference 2.

Case continued: ‘They’re hurting me’

Mr. N meets criteria for severe TBI. He is periodically agitated and aggressive and refuses to return to physical therapy, complaining that rehabilitation nurses are intentionally hurting him. He occasionally hits the staff and throws things. His medications include:

  • phenytoin, 100 mg every 6 hours for seizure prophylaxis
  • lamotrigine, 50 mg bid for seizure prophylaxis
  • zolpidem, 5 mg as needed at bedtime for pain
  • methadone, 10 mg/d for pain
  • oxycodone, 5 mg every 4 hours as needed for breakthrough pain.
Mr. N’s recovery 2 months after injury is rated as Rancho level IV, indicating that he remains confused and agitated. He requires maximal assistance with bed mobility and transfers, upper and lower extremity dressing, and rolling his wheelchair with both feet. He is incontinent of bowel and bladder.

Assessing progress

For patients such as Mr. N, TBI recovery progress is measured with the Rancho Los Amigos Scale.

The original Rancho scale—developed in 1972 by staff at the Rancho Los Amigos rehabilitation hospital in Downey, CA—described eight levels of cognitive and adaptive functioning, from coma and total care through normal cognition and independence. A 1997 revised version separates the highest cognitive functioning level (VIII, purposeful, appropriate function) into three parts, expanding the scale to 10 levels (Table 2).5

Of course, not all TBI patients begin recovery at Rancho level I, and unfortunately not all achieve level X. Some experience dementia caused by head trauma, with persistent memory impairment and cognitive deficits in language, apraxia, agnosia, or executive function.6

 

 

Most patients recover as predicted by the initial injury’s severity. Others experience diffuse cerebral swelling with sudden, rapid deterioration after what appeared to be a grade 1 or grade 2 concussion. Diffuse cerebral swelling is sometimes considered a “second-impact syndrome,” but it can also occur after a single impact.7 A second TBI is not universally believed to cause the precipitous decline, but animal studies suggest an additive effect of rapid sequential TBI.8

Table 2

10-level Rancho Los Amigos Scale for assessing TBI recovery

LevelCognitive and adaptive functionAssistance required
INo responseTotal assistance
IIGeneralized responseTotal assistance
IIILocalized responseTotal assistance
IVConfused/agitatedMaximal assistance
VConfused, inappropriate non-agitatedMaximal assistance
VIConfused, appropriateModerate assistance
VIIAutomatic, appropriateMinimal assistance
VIIIPurposeful, appropriateStand-by assistance
IXPurposeful, appropriateStand-by assistanceon request
XPurposeful, appropriateModified independent
Source: Traumatic Brain Injury Resource Guide. www.neuroskills.com.
Post-TBI syndromes. Concussion and TBI share diffuse axonal injury as a putative pathophysiologic mechanism. Post-concussion and post-TBI syndromes are similar but vary in severity and duration. Signs and symptoms include headache, light-headedness or dizziness, poor attention and concentration, irritability with low frustration tolerance, anxiety or depression, sensitivity to bright light or loud noise, and sleep disturbance.1

Recovery for a patient such as Mr. N with Rancho level IV to V TBI may be complicated by marked mood lability, spontaneous aggression, psychomotor agitation, extremely short attention with marked distractibility, little to no short-term memory, and noncooperation with treatment and care. Patients may also show disorders of diminished motivation, characterized by normal consciousness but decreased goal-directed behavior and affective flattening.9

Case continued: Calling in reinforcements

Besides combat nightmares, Mr. N is experiencing other signs of posttraumatic stress disorder (PTSD): intrusive memories of dead comrades, anhedonia, insomnia, irritability, and hypervigilance. We recommend a trial of citalopram, 10 mg/d, but within 1 week he becomes more irritable, agitated, and aggressive, with worsening sleep. We arrange a meeting to obtain collateral information from Mr. N’s aunt, mother, and clinical psychologist. We learn that a first-degree relative had bipolar disorder, and Mr. N lived with various relatives during childhood.

As a child, Mr. N was easily angered, hyperactive, unpredictably aggressive with peers, and impulsive. He was diagnosed with “explosive disorder” at age 8. A psychiatrist prescribed methylphenidate (which helped) and paroxetine (which worsened his behavior and aggression). Based on this history, we make a presumptive diagnosis of comorbid bipolar disorder.

Treating psychopathology

Comorbidities. Adolescents and adults with pre-existing attention-deficit/hyperactivity disorder or bipolar disorder may be predisposed to carelessness or risk taking that lead to accidents and TBI. Likewise, alcoholism and substance use disorders are risk factors for head injuries. These pre-existing conditions will complicate the post-TBI course and must be treated concurrently.

Depression and PTSD may follow a head injury and complicate recovery. In fact, post-TBI symptoms—poor sleep, poor memory and concentration, and irritability—are common to both depression and PTSD.

A team approach. Regardless of its severity or recovery stage, TBI requires multidisciplinary treatment. Physical, occupational, and speech therapies are essential initially. As recovery progresses, vocational rehabilitation may need to be added. Throughout rehabilitation, supportive individual and family therapy can help patients reintegrate into the community. Psychologists, neuropsychologists, and clinical social workers are indispensable to the treatment team.

Medication precautions

Using medications to manage post-TBI syndromes is difficult and controversial. No standard regimen exists, and few clinical trials guide treatment. Small, uncontrolled studies (human and animal) suggest commonly prescribed drugs may worsen outcomes (Table 3).10,11 For example:

  • Cognitive function improved in three TBI patients after thioridazine was discontinued in two and haloperidol in one.12
  • Haloperidol given to 11 patients with TBI made no difference in rehabilitation outcomes when compared with 15 patients who did not receive the antipsychotic. Those receiving haloperidol also had longer post-trauma amnesia (5 to 30 weeks), compared with the untreated group (1 to 18 weeks).13
  • In animal studies of TBI, motor recovery was slowed with haloperidol but not olanzapine,14,15 and with clonidine,16 phenytoin,17 and trazodone.18 Phenobarbitol.19 and diazepam20 have been associated with delayed behavioral recovery and chronic behavior problems, respectively, in rats with TBI. How these agents might affect human patients is speculative.
Table 3

Medications with potential to impede TBI recovery*

ClassMedications
Alpha-2 agonistClonidine
AntidepressantTrazodone
AntiepilepticPhenytoin, phenobarbital
BenzodiazepineDiazepam
NeurolepticHaloperidol, thioridazine
*Suggested by animal or clinical studies
Source: References 11-20
Apathy and inattention. A review of 63 papers found no strong evidence that drugs are effective for TBI’s neurobehavioral disorders, although weak evidence shows that some drug classes can reduce target symptoms—such as psychostimulants for apathy, inattention, and slowness (Table 4).21 Other reports suggest reasonable approaches:

  • Psychostimulants have improved recovery of motor function in animal trials if given before physical therapy.14
  • Stimulants and dopaminergic agonists such as bromocriptine and amantadine might help disorders of diminished motivation.22
  • Dextroamphetamine and methylphenidate have improved impulsivity, memory, and concentration in a patient with TBI.23
 

 

Table 4

Drugs considered safe and effective
for TBI neurobehavioral symptoms

Target symptom(s)DrugUsual daily dosage*
ApathyAmantadine100 to 400 mg
Bromocriptine1.25 to 100 mg
CognitionDonepezil 
InattentionDextroamphetamine5 to 60 mg
Methylphenidate10 to 60 mg
Depression, PTSD symptomsFluoxetine20 to 80 mg
Agitation, mood stabilizationAnticonvulsants 
Lamotrigine25 to 200 mg
Divalproex sodium10 to 15 mg/kg/day
Carbamazepine400 to 1,600 mg
Atypical antipsychotics 
Olanzapine2.5 to 20 mg
Quetiapine50 to 800 mg
Risperidone0.5 to 6 mg
Ziprasidone20 to 160 mg
Beta blocker 
Propranolol20 to 480 mg
PTSD: posttraumatic stress disorder
* Dosage may be divided; see full prescribing information.
† Adjust dosage to achieve serum level of 50 to 100 mcg/mL.
‡ Adjust dosage to achieve serum level of 4 to 12 mcg/mL.
Agitation and aggression in TBI are more difficult to treat than apathy or inattention. Some authors15,24 suggest that atypical antipsychotics are more effective than neuroleptics for these symptoms and less likely to cause adverse effects (Table 5).

Small studies of anticonvulsants for post-TBI agitation report:

  • valproic acid might improve behavioral control and decrease aggression, and it did not worsen performance on neuropsychological testing
  • carbamazepine reduced agitation in seven TBI patients and reduced anger outbursts in 8 of 10 others
  • gabapentin caused paradoxical effects in two TBI patients25
  • lamotrigine improved agitation in one TBI patient.26
Five studies show preliminary evidence that beta blockers (usually propranolol) can reduce assaultive behavior and temper outbursts in TBI patients. Relatively high dosages are usually needed, such as:

  • propranolol, 420 to 520 mg/d
  • pindolol, 60 mg/d
  • metoprolol, 200 mg/d.21
Table 5

Dosing atypical antipsychotics
for agitation and aggression in TBI

DrugInitial daily dosage*Maximum daily dosage*
Aripiprazole2.5 to 5 mg30 mg
Olanzapine2.5 mg20 mg
Quetiapine12.5 to 50 mg800 mg
Risperidone0.25 mg8 mg
Ziprasidone20 mg160 mg
*Daily dosages may be divided
Psychiatric comorbidity. In TBI patients with comorbid bipolar disorder, mood stabilization with an atypical antipsychotic, anticonvulsant (divalproex sodium, carbamazepine), or a combination of the two is first-line therapy. No evidence suggests that using lithium in the absence of mania improves aggression, agitation, or other neurobehavioral symptoms in TBI patients.21

Depression and PTSD in TBI patients are considered indications for selective serotonin reuptake inhibitors (SSRIs). Animal data suggest that fluoxetine is safe for patients with TBI,27 though no human data have been published.

For PTSD with bipolar depression, we usually prescribe lamotrigine or combine an atypical antipsychotic with an SSRI. Lithium would be second-line therapy. PTSD with bipolar mania is more difficult to treat because little evidence guides medication choices. As with depression and PTSD, we usually combine an atypical antipsychotic with an SSRI. We try to control manic and psychotic symptoms first, then add the SSRI for anxiety after the mood becomes more stable.

Cognitive impairment. A dozen published studies and case reports indicate that donepezil improves cognition in subacute and chronic TBI. For example:

  • An open-label trial showed subjective improvement in cognitive functions in 8 of 10 patients given donepezil.28
  • In a double-blind, placebo-controlled, crossover trial, short-term memory and attention improved with donepezil in 18 patients with post-acute TBI, as shown by neuropsychological test scores.29
  • A retrospective case-control study showed no significant difference in cognitive outcome between controls and 18 patients prescribed donepezil but did suggest that cognition improved more rapidly when patients started donepezil earlier in recovery.30

Case continued: Back to rehab

We replace Mr. N’s phenytoin with carbamazepine, 700 mg/d (serum level about 12 mcg/mL), discontinue citalopram, and start him on quetiapine as a mood stabilizer, titrating the dosage to 600 mg/d over 3 weeks. We select quetiapine based on experience using it as a mood stabilizer and carbamazepine for additional mood stabilization and seizure prophylaxis.

We continue methadone and oxycodone at the same dosages for pain management, with good results. We eventually switch him from zolpidem to trazodone, 50 mg as needed at bedtime. We discontinue lamotrigine because he is no longer having seizures.

Mr. N tolerates quetiapine and carbamazepine well. The nursing staff reports he is much less irritable and aggressive and his sleep has improved, but he is not oversedated. He returns to and participates in physical, occupational, and speech therapies.

Tips for using medications

Many TBI patients are unusually sensitive to or intolerant of medication side effects. Because no randomized, controlled clinical trials support using any medication in these patients, be cautious. The following recommendations can help:

  • Use psychotropics with a low risk of complications.
  • Start with low dosages and increase gradually to assess side effects and efficacy of medication trials.
  • Give full trials and adequate dosing before you decide a medication has not improved symptoms sufficiently.
  • Monitor closely for side effects.
  • Seek information from family members to evaluate a medication’s effectiveness, as patients’ cognitive deficits may limit their ability to reliably report symptoms.
 

 

Related resources

  • Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press, 2005.
  • Traumatic Brain Injury Resource Guide. www.neuroskills.com
Drug brand names

  • Amantadine • Symmetrel
  • Bromocriptine • Parlodel
  • Carbamazepine • Tegretol
  • Citalopram • Celexa
  • Clonidine • Catapres
  • Dextroamphetamine • Dexedrine
  • Diazepam • Valium
  • Divalproex sodium • Depakote
  • Donepezil • Aricept
  • Fluoxetine • Prozac
  • Gabapentin • Neurontin
  • Haloperidol • Haldol
  • Lamotrigine • Lamictal
  • Methadone • Dolophine
  • Methylphenidate • Ritalin
  • Metoprolol • Lopressor
  • Olanzapine • Zyprexa
  • Oxycodone • Oxycontin
  • Paroxetine • Paxil
  • Phenobarbital • Luminal
  • Phenytoin • Dilantin
  • Pindolol • Visken
  • Propranolol • Inderal
  • Quetiapine • Seroquel
  • Risperidone • Risperdal
  • Thioridazine • Mellaril
  • Trazodone • Desyrel
  • Ziprasidone • Geodon
  • Zolpidem • Ambien
Disclosures

The author reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References

1. American Academy of Neurology. Practice parameter: The management of concussion in sports. Neurology 1997;48:581-5.

2. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974;2(7872):81-4.

3. Alexander MP. Mild traumatic brain injury: Pathophysiology, natural history, and clinical management. Neurology 1995;45:1253-60.

4. Arlinghaus KA, Shoaib AM, Price TRP. Neuropsychiatric assessment. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press; 2005:59-78.

5. Hagen C, Malkmus D, Durham P. Communication Disorders Service, Rancho Los Amigos Rehabilitation Hospital, Downey, CA, 1972 (rev. 1997).

6. Diagnostic and statistical manual of mental disorders (4th ed, text rev). Washington, DC: American Psychiatric Association; 2000.

7. McCrory P. Does second impact syndrome exist? Clin J Sport Med 2001;11:144-9.

8. Vagnozzi R, Signoretti S, Tavazzi B, et al. Hypothesis of the postconcussive vulnerable brain: experimental evidence of its metabolic occurrence. Neurosurgery 2005;57:164-71.

9. Marin RS, Chakravorty S. Disorders of diminished motivation. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA; American Psychiatric Press; 2005:337-52.

10. Goldstein LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry 1995;58:753-5.

11. Phillips JP, Devier DJ, Feeney DM. Rehabilitation pharmacology bridging laboratory work to clinical application. J Head Trauma Rehabil 2003;18:342-56.

12. Stanislaw SL. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Injury 1997;11:335-41.

13. Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil 1985;66:30-4.

14. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-7.

15. Wilson MS, Gibson CL, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003;82:871-9.

16. Goldstein LB, Davis JN. Clonidine impairs recovery of beamwalking after a sensorimotor cortex lesion in the rat. Brain Research 1990;508:305-9.

17. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Research 1986;376:71-7.

18. Boyeson MG, Harmon RL. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil 1993;72:286-93.

19. Hernandez TD, Holling LC. Disruption of behavioral recovery by the anticonvulsant phenobarbital. Brain Research 1994;635:300-6.

20. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Research 1986;379:104-11.

21. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behavior disorders in traumatic brain injury patients. Brain Injury 2004;18:1-31.

22. Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatric Annals 1997;27(1):44-9.

23. Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987;175:106-10.

24. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil 2003;18:177-95.

25. Lombard LA, Zafonte RD. Agitation after traumatic brain injury: considerations and treatment options. Am J Phys Med Rehabil 2005;84:797-812.

26. Pachet A, Friesen S, Winkelaar D, Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Injury 2003;17:715-22.

27. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline, and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil 1994;73:76-83.

28. Khateb A, Ammann J, Annoni JM, Diserens K. Cognition enhancing effects of onepezil in traumatic brain injury (abstract). Eur Neurol 2005;54:39-45.

29. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004;85:1005-55.

30. Walker W, Seel R, Gibellato M, et al. The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj 2004;18:739-50.

References

1. American Academy of Neurology. Practice parameter: The management of concussion in sports. Neurology 1997;48:581-5.

2. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974;2(7872):81-4.

3. Alexander MP. Mild traumatic brain injury: Pathophysiology, natural history, and clinical management. Neurology 1995;45:1253-60.

4. Arlinghaus KA, Shoaib AM, Price TRP. Neuropsychiatric assessment. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA: American Psychiatric Press; 2005:59-78.

5. Hagen C, Malkmus D, Durham P. Communication Disorders Service, Rancho Los Amigos Rehabilitation Hospital, Downey, CA, 1972 (rev. 1997).

6. Diagnostic and statistical manual of mental disorders (4th ed, text rev). Washington, DC: American Psychiatric Association; 2000.

7. McCrory P. Does second impact syndrome exist? Clin J Sport Med 2001;11:144-9.

8. Vagnozzi R, Signoretti S, Tavazzi B, et al. Hypothesis of the postconcussive vulnerable brain: experimental evidence of its metabolic occurrence. Neurosurgery 2005;57:164-71.

9. Marin RS, Chakravorty S. Disorders of diminished motivation. In: Silver JM, McAllister TW, Yudofsky SC (eds). Textbook of traumatic brain injury. Arlington, VA; American Psychiatric Press; 2005:337-52.

10. Goldstein LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry 1995;58:753-5.

11. Phillips JP, Devier DJ, Feeney DM. Rehabilitation pharmacology bridging laboratory work to clinical application. J Head Trauma Rehabil 2003;18:342-56.

12. Stanislaw SL. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Injury 1997;11:335-41.

13. Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil 1985;66:30-4.

14. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-7.

15. Wilson MS, Gibson CL, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003;82:871-9.

16. Goldstein LB, Davis JN. Clonidine impairs recovery of beamwalking after a sensorimotor cortex lesion in the rat. Brain Research 1990;508:305-9.

17. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Research 1986;376:71-7.

18. Boyeson MG, Harmon RL. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil 1993;72:286-93.

19. Hernandez TD, Holling LC. Disruption of behavioral recovery by the anticonvulsant phenobarbital. Brain Research 1994;635:300-6.

20. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Research 1986;379:104-11.

21. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behavior disorders in traumatic brain injury patients. Brain Injury 2004;18:1-31.

22. Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatric Annals 1997;27(1):44-9.

23. Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987;175:106-10.

24. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil 2003;18:177-95.

25. Lombard LA, Zafonte RD. Agitation after traumatic brain injury: considerations and treatment options. Am J Phys Med Rehabil 2005;84:797-812.

26. Pachet A, Friesen S, Winkelaar D, Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Injury 2003;17:715-22.

27. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline, and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil 1994;73:76-83.

28. Khateb A, Ammann J, Annoni JM, Diserens K. Cognition enhancing effects of onepezil in traumatic brain injury (abstract). Eur Neurol 2005;54:39-45.

29. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004;85:1005-55.

30. Walker W, Seel R, Gibellato M, et al. The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj 2004;18:739-50.

Issue
Current Psychiatry - 05(05)
Issue
Current Psychiatry - 05(05)
Page Number
57-68
Page Number
57-68
Publications
Publications
Article Type
Display Headline
Traumatic brain injury: Choosing drugs to assist recovery
Display Headline
Traumatic brain injury: Choosing drugs to assist recovery
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media